Novartis India to Acquire Pfizer’s Minipress Trademarks for Rs 1,250 Crore

Novartis India Ltd has approved the acquisition of the “Minipress” and “Minipres” trademarks from Pfizer Inc., USA, and Pfizer Products Inc., USA, in a transaction valued at approximately Rs 1,250 crore. The move will transfer ownership of the trademarks registered in India, along with certain associated intellectual property rights, to Novartis India.

According to a regulatory filing, Novartis India’s Board of Directors approved the transaction, following which the company entered into an asset purchase agreement and trademark assignment deeds with the two Pfizer entities. The signing and closing of the transaction are expected to take place simultaneously.

The acquisition strengthens Novartis India’s position in the established cardiovascular and urology medicine segment. The Minipress brand is associated in India with Minipress XL, a formulation containing prazosin. The medicine is primarily indicated for the treatment of hypertension, or high blood pressure, and for managing urinary symptoms associated with benign prostatic hyperplasia (BPH).

Minipress XL has maintained a notable commercial presence in the Indian pharmaceutical market. Data from several media reports showed that the product generated revenue of Rs 228.6 crore. The product has also recorded a compound annual growth rate of 6.3% over the past four years, highlighting continued demand for the brand despite operating in an established therapeutic category.

The transaction comes as Pfizer prepares to discontinue its involvement with Minipress XL in India. In a separate regulatory filing, Pfizer Ltd stated that it would stop the marketing, distribution and sale of Minipress XL with immediate effect. The company attributed the decision to Pfizer Inc. USA’s plan to discontinue manufacturing the product.

The transfer of the trademarks could allow Novartis India to assume control of the brand and potentially maintain its market presence, subject to the completion of the transaction and relevant regulatory and commercial requirements. The deal also provides Novartis with access to an established product with a long operating history and an existing revenue base in India.

From a broader pharmaceutical market perspective, the transaction reflects the continued reshaping of branded drug portfolios through trademark and asset transfers. For Novartis, acquiring the Minipress and Minipres marks could support its presence in the hypertension and BPH treatment segments, while Pfizer’s exit represents a strategic withdrawal from the product following its manufacturing decision.

Product impact: The acquisition gives Novartis India control of the established Minipress and Minipres trademarks and could support continued commercialization of Minipress XL, which contains prazosin. Pfizer’s withdrawal may temporarily disrupt supply during the transition, but Novartis’ ownership could provide continuity if production and distribution are maintained.

Amlodipine Besylate price impact: The effect on Amlodipine Besylate prices tracked by ChemAnalyst is expected to be negligible to none. Minipress XL contains prazosin, not Amlodipine Besylate. While both medicines are used for hypertension, they have different active pharmaceutical ingredients and mechanisms. Therefore, this trademark transaction is unlikely to materially change Amlodipine Besylate demand, supply, or pricing fundamentals.